drug development. Drug discovery FCDI cells enable new strategies for disease modeling and drug discovery work. Because FCDI's MyCell Products are created using custom iPS cell reprogramming and differentiation processes, they provide biologically relevant human cells from donors with specific disease-associated genotypes and phenotypes. The company's iCell and MyCell cells are readily adapted to screening platforms and demonstrate functionality using widely accepted readout technologies. FCDI's products are used in high throughput screens, and have been used as supporting data in Investigational New Drug (IND) submissions to the FDA. Regenerative medicine Reprogramming technology enables new ways to study disease mechanisms and modeling. Researchers can reprogram diseased cells of interest to study how a particular disease affects those cell types and to discover methods of repairing the cells. FCDI's iCell and MyCell products are being used to research the development of regenerative medicine approaches, including: regenerative medicine compound screening, allogeneic and autologous cell therapy, tissue engineering, and transplantation. Specifically in the area of tissue engineering, FCDI's iCell and MyCell products are being employed across a variety of technologies, such as implantable devices, de-cellularized organ reconstitution and 3D bioprinting. Stem cell banking FCDI is actively engaged in a number of large-scale iPS cell reprogramming and banking projects, with the goal of creating broadly available resources of iPS cells that represent normal human diversity, disease states and adverse drug reactions. In 2013, CIRM awarded FCDI a grant to derive 3 iPS cell lines from each of 3,000 donors that represent a multitude of disease states. This project follows a $6.3 million grant awarded by the National Heart, Lung, and Blood Institute to FCDI and the Medical College of Wisconsin to investigate the mechanisms underlying left ventricular hypertrophy. FCDI's role in this project is to generate iPS cell lines and cardiomyocytes from 250 donors selected from the Hypertension Genetic Epidemiology Network (HyperGEN) GWAS study. Product areas Cardiac The company's first product, iCell Cardiomyocytes, have been used extensively in pharmaceutical research and drug development applications. Other stem cell derived Cardiomyocytes are available commercially from GE Healthcare, Cellectis, Reprocell and others. iCell Cardiomyocytes have been found to display electrical properties similar to those of human cardiomyocytes. iCell Cardiomyocytes have also been used for drug safety testing, toxicology testing, drug screening and Investigational New Drug (IND) filings. iCell Cardiac Progenitor Cells (CPCs) are part of the FCDI Cardiac portfolio; these cells launched in 2014 for use in heart